![Zina Affas Besse](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Zina Affas Besse
Directeur/Bestuurslid bij Alydia Health, Inc.
Profiel
Zina Affas Besse has held various director positions in companies such as Eyenuk, Inc., Alydia Health, Inc., and LimmaTech Biologics AG.
She is also an advisor at LHGP Asset Management LLP (Private Equity).
Actieve functies van Zina Affas Besse
Bedrijven | Functie | Begin |
---|---|---|
Alydia Health, Inc.
![]() Alydia Health, Inc. Medical SpecialtiesHealth Technology Alydia Health, Inc. operates as medical device company which provides solution to postpartum hemorrhage. The company was founded by Nathan Bair and Jessie Becke on May 8, 2018 and is headquartered in Menlo Park, CA. | Directeur/Bestuurslid | - |
Eyenuk, Inc.
![]() Eyenuk, Inc. Medical SpecialtiesHealth Technology Eyenuk, Inc. provides health care services. The firm focuses on identifying patients suffering from potentially blinding eye diseases and preserving their vision. It is developing a portfolio of products based on its proprietary retinal image analysis technology. Its products include EyeArt, EyeMark, EyeApp, and EyeSeeAMD. The company was founded by Kaushal Solanki in 2010 and is headquartered in Woodland Hills, CA. | Directeur/Bestuurslid | 17-10-2022 |
LHGP Asset Management LLP (Private Equity)
![]() LHGP Asset Management LLP (Private Equity) Investment ManagersFinance LHGP Asset Management LLP (Private Equity) (LHGP Asset Management) is a private equity arm of Lion's Head Global Partners LLP founded in 2018. The firm is headquartered in Westminster, United Kingdom. | Consultant / Adviseur | - |
LimmaTech Biologics AG
![]() LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Directeur/Bestuurslid | 09-10-2023 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
Alydia Health, Inc.
![]() Alydia Health, Inc. Medical SpecialtiesHealth Technology Alydia Health, Inc. operates as medical device company which provides solution to postpartum hemorrhage. The company was founded by Nathan Bair and Jessie Becke on May 8, 2018 and is headquartered in Menlo Park, CA. | Health Technology |
Eyenuk, Inc.
![]() Eyenuk, Inc. Medical SpecialtiesHealth Technology Eyenuk, Inc. provides health care services. The firm focuses on identifying patients suffering from potentially blinding eye diseases and preserving their vision. It is developing a portfolio of products based on its proprietary retinal image analysis technology. Its products include EyeArt, EyeMark, EyeApp, and EyeSeeAMD. The company was founded by Kaushal Solanki in 2010 and is headquartered in Woodland Hills, CA. | Health Technology |
LHGP Asset Management LLP (Private Equity)
![]() LHGP Asset Management LLP (Private Equity) Investment ManagersFinance LHGP Asset Management LLP (Private Equity) (LHGP Asset Management) is a private equity arm of Lion's Head Global Partners LLP founded in 2018. The firm is headquartered in Westminster, United Kingdom. | Finance |
LimmaTech Biologics AG
![]() LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Commercial Services |